Sign in

ARTL on Nasdaq

ARTELO BIOSCIENCES, INC.

American pharmaceutical preparations company based in Solana Beach1

In its 2026 annual report the company says: “We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system, a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. Our programs represent a comprehensive approach in utilizing the power and promise of lipid signaling to develop pharmaceuticals for patients with unmet healthcare needs.”3 Its shares trade on Nasdaq under the symbol ARTL.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerARTL on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSolana Beach, California1
  • Incorporated inNV2
  • Business address505 Lomas Santa Fe, Suite 160, Solana Beach, Ca 920752
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$11.4M in 2025+255% since 2019
-$15.0M-$10.0M-$5.0M02019: -$3.2M-$3.2M20192020: -$4.7M-$4.7M2020+46%2021: -$9.4M-$9.4M2021+101%2022: -$10.3M-$10.3M2022+9%2023: -$9.9M-$9.9M2023−3%2024: -$10.1M-$10.1M2024+2%2025: -$11.4M-$11.4M2025+13%
Net income456789-$12.9M in 2025+493% since 2019
-$15.0M-$10.0M-$5.0M02019: -$2.2M-$2.2M20192020: -$4.7M-$4.7M2020+114%2021: -$9.4M-$9.4M2021+102%2022: -$10.1M-$10.1M2022+7%2023: -$9.3M-$9.3M2023−8%2024: -$9.8M-$9.8M2024+6%2025: -$12.9M-$12.9M2025+31%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
General and administrative$6.0M$4.1M
Research and development$5.4M$6.0M
Total Operating Expenses$11.4M$10.1M
Loss from Operations-$11.4M-$10.1M
Gain on investment$22.0K$0
Interest expense-$194.0K$0
Interest expense - related party-$83.0K$0
Loss on extinguishment of debt-$825.0K$0
Loss on extinguishment of debt - related party-$333.0K$0
Net change in fair value of digital assets-$62.0K$0
Net change in fair value of trading marketable securities$0$282.0K
Total other (expense) income-$1.5M$282.0K
Provision for income taxes$0$0
NET LOSS-$12.9M-$9.8M
Foreign currency translation adjustments-$70.0K$1.0K
Total Other Comprehensive Income (Loss)-$70.0K$1.0K
TOTAL COMPREHENSIVE LOSS-$12.9M-$9.8M
Basic and Diluted Loss per Common Share-$12.52-$18.30
Basic and Diluted Weighted Average Common Shares Outstanding1.0M shares537.0K shares

Compare ARTELO BIOSCIENCES, INC. with another company

Corporate structure

ARTELO BIOSCIENCES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ARTELO BIOSCIENCES, INC.

  • ARTELO BIOSCIENCES, INC. Solana Beach, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ARTELO BIOSCIENCES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$64.0K9 Dec 31, 2025$99.0K9 Dec 31, 2024−35.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$600.0K9 Dec 31, 2025$6.9M6 Dec 31, 2022−91.3%
Marketable securities, current$08 Dec 31, 2024$7.6M8 Dec 31, 2023−100.0%
Marketable securities, non-current$08 Dec 31, 2024$7.6M8 Dec 31, 2023−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$2.0M9 Dec 31, 2025$2.0M9 Dec 31, 20240%

Properties, in its own words

Our principal executive office is currently located at 505 Lomas Santa Fe, Suite 160, Solana Beach, California 92075, USA. Our United Kingdom subsidiary, Artelo Biosciences Limited maintains an office at the biohub located at Mereside, Alderly Park, Alderly Edge, Cheshire, SK10 4TG, UK. The Solana Beach facility is approximately 800 square feet and the United Kingdom facility is approximately 800 square feet. We do not currently own any real property, including laboratories or manufacturing facilities. We believe our current facilities are sufficient to meet our current needs.

Item 2 of the 10-K filed Feb 24, 2026.3

Leadership

Who has led ARTELO BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gregory D. Gorgas2019–now

President

  1. Gregory D. Gorgas2025–now

Chief financial officer

  1. Gregory D. Gorgas2019–now
20202025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerMark R. Spring named Nov 10, 2025 to Apr 6, 202621
  • DirectorGregory R. Reyes named May 20, 2022 to Apr 6, 202621
  • DirectorR. Martin Emanuele named May 20, 2022 to Apr 6, 202621
  • DirectorSteven D. Kelly named May 20, 2022 to Apr 6, 202621
  • DirectorTamara A. Favorito named Jul 9, 2025 to Apr 6, 202621

Former names

  • REACTIVE MEDICAL INC.Feb 10, 2017 to Apr 17, 20172
  • KNIGHT KNOX DEVELOPMENT CORP.Oct 8, 2014 to Feb 6, 20172

Timeline

  1. Oct 9, 20268-K Other events22
  2. Aug 27, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure23
  3. Jul 17, 20268-K Shareholder vote24
  4. May 27, 20268-K Entered a material agreement; Other events25
  5. May 15, 20268-K Ended a material agreement26
  6. Apr 7, 20268-K Other events27
  7. Mar 30, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure28
  8. Mar 26, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure29
  9. Mar 18, 20268-K Entered a material agreement; Unregistered sale of shares30
  10. Mar 17, 20268-K Results of operations; Other events31
  11. Mar 6, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events32
  12. Feb 5, 20268-K Other events33
  13. Jun 21, 2019New chief executive Gregory D. Gorgas becomes CEO12

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202634

When it reported results

  1. Mar 17, 2026Reported quarterly or annual results31
  2. Jul 11, 2025Reported quarterly or annual results35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

228 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 51 major events, 58 insider forms, 11 large holders, 9 private raises, 77 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Aug 27, 20268-K EDGAR
  3. Aug 20, 202610-Q/A EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 13, 2026SCHEDULE 13G/A EDGAR
  6. Aug 12, 202610-Q EDGAR
  7. Jul 21, 20264 EDGAR
  8. Jul 21, 20264 EDGAR
  9. Jul 21, 20264 EDGAR
  10. Jul 21, 20264 EDGAR
  11. Jul 21, 20264 EDGAR
  12. Jul 21, 20264 EDGAR
  13. Jul 17, 20268-K EDGAR
  14. Jul 16, 2026DEFA14A EDGAR
  15. Jul 16, 2026DEFA14A EDGAR
  16. Jul 2, 2026DEFA14A EDGAR
  17. Jun 22, 2026PRER14A PRER 14A EDGAR
  18. Jun 5, 2026ARS EDGAR
  19. Jun 5, 2026DEFA14A EDGAR
  20. Jun 5, 2026DEF 14A EDGAR

The 228 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 12, 2022Gorgas Gregory D.Pres, CEO, CFO, Treas & SecrBuy1,200$4.00$4.8KForm 4
Aug 11, 2022Gorgas Gregory D.Pres, CEO, CFO, Treas & SecrBuy1,200$4.03$4.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Gregory D. GorgasPresident, CEO, Secretary,63$540.0K$1.2M42
2025Mark E. Spring,67$41.7K$290.5K42
2024and Director and Former CFO and Treasurer$520.0K$1.1M42
2024CFO and Treasurer$813$81342

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 27, 2026Raised $11 million in a private offering of equity Form D: 2 investors so far Form D
  2. Mar 20, 2026Raised $315,000 in a private offering of debt Form D: 1 investor so far Form D
  3. Mar 12, 2026Raised $237,300 in a private offering of debt Form D: 1 investor so far Form D
  4. Mar 12, 2026Raised $113,000 in a private offering of debt Form D: 1 investor so far Form D
  5. Jan 30, 2026Raised $500,000 in a private offering of equity Form D: $50.5 million offered in all Form D
  6. Oct 28, 2025Raised $3.7 million in a private offering of debt Form D: 14 investors so far Form D
  7. Aug 5, 2025Raised $9.5 million in a private offering of equity Form D: 18 investors so far Form D
  8. Jun 26, 2025Raised $1.4 million in a private offering of equity Form D: 8 investors so far Form D
  9. May 13, 2022Raised $96,972 in a private offering of equity Form D: $20.1 million offered in all Form D

SEC filer profile

How ARTELO BIOSCIENCES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARARTELO BIOSCIENCES, INC.1
  • CIK0001621221
  • Employer ID (EIN)33-12209243
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address505 Lomas Santa Fe, Suite 160, Solana Beach, CA 920751
  • Phone858-925-70491
  • Shares outstanding4,595,068 as of Aug 11, 202643
  • Public float$9.3M as of Jun 30, 20253
  • AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 8, 20141
  • Filings465 in all: 8-K (98), 4 (89), 10-Q (35), CORRESP (23), EFFECT (19), UPLOAD (18), D (15), S-1/A (14)1
    All 44 form types

    SC 13G (14), 424B5 (13), 3 (12), 10-K (11), S-1 (11), DEF 14A (9), DEFA14A (9), SC 13G/A (9), S-8 (7), PRE 14A (5), S-3 (5), 10-Q/A (4), 424B3 (4), ARS (4), POS AM (4), S-3/A (4), CT ORDER (3), SCHEDULE 13D/A (3), 10-K/A (2), 424B4 (2), DRS (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 10-KT (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), CERT (1), DEL AM (1), FWP (1), NT 10-K (1), NT 10-Q (1), PRER14A (1), RW (1), S-1MEF (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Jun 5, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareARTLNasdaq

From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks ARTELO BIOSCIENCES, INC. names in Item 1A of its 10-K filed Feb 24, 2026: 60 risks under these headings, as written.3

  • RISKS RELATED TO OUR BUSINESS AND PRODUCT CANDIDATES
  • Our financial condition raises substantial doubt as to our ability to continue as a going concern.
  • The Company will need to raise additional financing to support our business objectives. The Company cannot be sure the Company will be able to obtain additional financing on terms favorable to us when needed, or at all. If the Company is unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated.
  • The Company is currently receiving Research and Development (“R&D”) tax credits from the UK in connection with its activities in the UK. The value of these will likely decrease and there is an increased risk payments may be significantly delayed.
  • If the Company fails to comply with our obligations under our patent licenses with third parties, the Company could lose license rights that are vital to our business.
  • Changes in regulatory requirements or other unforeseen circumstances may impact the timing of the initiation or completion of our clinical trials.
  • The Company does not have any therapeutic products that are approved for commercial sale. Our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of areas.
  • The Company has very limited operating history and capabilities.
  • The Company may experience delays in providing sufficient product for future testing of our candidates due to prior and any future supply chain limitations caused by pandemics.
  • After submitting Investigational New Drug applications, the FDA may not permit us to proceed in a timely manner, or at all.
  • Use of our product candidates could be associated with adverse side effects.
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and clinical trials may not be predictive of future clinical trial results, and our clinical trials may fail to adequately demonstrate substantial evidence of safety and efficacy of our product candidates.
The other 49 risks
  • Interim, topline and preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Due to our limited resources, the Company may be forced to focus on a limited number of development candidates which may force us to pass on opportunities that could have a greater chance of clinical success.
  • The Company will need to rely on third parties to conduct our preclinical research and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such research or trials.
  • The Company currently has no marketing and sales organization and has no experience in marketing products. If the Company is unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved in the future, the Company may not be able to generate product revenue.
  • If our contract manufacturing organization for materials to be used in our clinical trials fails to supply us with the necessary materials, the Company may be unable to complete our clinical trials on a timely basis, if at all.
  • Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
  • The Company may depend on third parties for clinical and commercial supplies, including, in some instances, a single supplier.
  • If any of our offices become damaged or inoperable, or the Company is required to vacate our facilities, our ability to pursue our research and development efforts may be jeopardized.
  • Even if the Company is successful in licensing or developing research programs and/or product candidates, the Company or our licensors must maintain the intellectual property.
  • The costs and other requirements associated with filing new patent applications, and the ongoing cost of prosecuting pending patent applications and maintenance of issued patents are material to us. Bearing these costs and complying with these requirements are essential to procurement and maintenance of patents integral to our product candidates.
  • Our ability to research, develop and commercialize any product candidates is dependent on our ability to acquire, maintain or utilize third party contract research facilities that possess licenses relating to controlled substances and the dispensing of prescription products.
  • Any product candidates the Company develops may be subject to U.S. controlled substance laws and regulations and similar controls in territories outside the U.S. where the Company is conducting research. Failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition.
  • DEA registration and inspection of facilities.
  • State-controlled substances laws.
  • Manufacturing in the United States.
  • Distribution in the United States.
  • Our product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue.
  • Results of preclinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
  • Clinical trials of lipid-signaling modulators and cannabinoid-based product candidates are novel with very limited or non-existing history; the Company faces a significant risk that the trials will not result in commercially viable products and treatments.
  • Changes in consumer preferences and acceptance of cannabinoid-derived products and any negative trends will adversely affect our business.
  • Our product candidates may contain controlled substances, the use of which may generate public controversy.
  • Laws and regulations affecting therapeutic uses of cannabinoids are constantly evolving.
  • Cannabinoid-based research activities in the pharmaceutical industry may make it difficult to obtain insurance coverage.
  • The Company faces a potentially highly competitive market.
  • Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.
  • The Company is highly dependent on our key personnel, and if the Company is not successful in attracting and retaining highly qualified personnel, the Company may not be able to successfully implement our business strategy.
  • The Company will need to grow the size and capabilities of our organization, and the Company may experience difficulties in managing this growth.
  • The Company is currently reliant on consultants to oversee critical activities and perform services on behalf of the Company.
  • The Company has incurred losses since inception and cannot assure that the Company will ever achieve or sustain profitability.
  • If our information technology systems or data, or those of third parties upon which we depend, are compromised, adverse consequences may follow. These consequences include business operation disruptions, litigation, regulatory investigations or actions, fines and penalties, reputational harm, and financial losses.
  • Our employees or consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • The Company may not successfully manage our growth.
  • RISKS RELATED TO OUR INTELLECTUAL PROPERTY
  • If the Company is unable to obtain and maintain patent protection for our products, our competitors could develop and commercialize products and technology similar or identical to our product candidates, and our ability to successfully commercialize any product candidates the Company may develop, and our science may be adversely affected.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural measures, document submissions, fee payments and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • The Company may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • Intellectual property rights do not necessarily address all potential threats.
  • Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • The Company may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • RISKS RELATED TO OUR SECURITIES
  • Our Common Stock may be delisted from The Nasdaq Capital Market if the Company cannot maintain compliance with Nasdaq’s continued listing requirements.
  • The price of our securities may be volatile, and you could lose all or part of your investment. Further, the Company does not know whether an active, liquid and orderly trading market will continue for our securities or what the market price of our securities will be and as a result it may be difficult for you to sell your shares of our securities.
  • Shares of our Common Stock that have not been registered under federal securities laws are subject to resale restrictions imposed by Rule 144, including those set forth in Rule 144(i) which apply to a former “shell company.”
  • Sales of our currently issued and outstanding stock may become freely tradable pursuant to Rule 144 and sales of such shares may have a depressive effect on the share price of our Common Stock.
  • The Company does not plan to declare or pay any dividends to our stockholders in the near future.
  • The Company incurs significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives.
  • Future changes in financial accounting standards or practices may cause adverse unexpected financial reporting fluctuations and affect reported results of operations.
  • Our disclosure controls and procedures may not be effective to ensure that the Company makes all required disclosures.
  • Anti-takeover provisions in our amended and restated articles of incorporation and bylaws, as well as provisions in Nevada law, might discourage, delay, or prevent a change of control of our company or changes in our management and, therefore, depress the trading price of our securities.
  • The Company is a smaller reporting company, and the Company cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our securities less attractive to investors.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.

Legal proceedings

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business, financial condition, and results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43